

An efficient total synthesis of vilanterol: an inhaled drug

Kamalaker Reddy Kamireddy,^a Sailam Sri Gogula,^a Venkateswarlu Banoji,^a Sayaji Rao,^a and Balakishan Gorre^{b*}

^aUniversity College of Science, Osmania University, Hyderabad, India-500007

^bDepartment of Chemistry, University College of Science, Telangana University, Telangana, India-503322

Email: gbk@telanganauniversity.ac.in

This article is dedicated to Prof. Dr. Ahmad Kamal for his outstanding contribution to organic synthesis, chemical biology and medicinal chemistry


Received 12-24-2022

Accepted Manuscript 08-01-2023

Published on line 08-17-2023

Abstract

Total synthesis of vilanterol, a long-acting β_2 -adrenoceptor agonist and potent drug for chronic obstructive pulmonary disease & asthma is accomplished efficiently by a novel method. In this synthesis, the key intermediate oxazolidinone compound is prepared using convenient and efficient reaction methods including Friedel-Crafts acylation, chemo-selective reduction, Corey-Itsuno reduction and oxazolidinone ring formation. The oxazolidinone was coupled with an alkyl bromide and then selective deprotections produced vilanterol in satisfactory yield.




Keywords: Vilanterol, salicylaldehyde, β_2 -adrenoceptor agonists drug, total synthesis

Introduction

Pulmonary infections caused by inflammatory responses are becoming a prominent cause of mortality across the globe; ¹ asthma and chronic obstructive pulmonary disease (COPD) are traditionally thought to be two different respiratory illnesses. ² β_2 -Adrenoceptor (β_2 -AR) agonists are indeed the main class of drugs used to treat both asthma and COPD by enhancing airflow into the lungs through regulating the airways. ³ This class is further subdivided into long-acting and short-acting β_2 -AR agonists depending on the length of time and effect. ⁴ All these β_2 -AR agonists show bronchodilating properties. ⁵⁻⁶

Vilanterol is a novel, ultra-long-acting β_2 -adrenoceptor agonist used as first-line therapy for asthma and COPD (chronic obstructive pulmonary disease). ⁷ Its pharmacological effect is due to stimulation of β_2 -adrenoceptor in the lungs which triggers the enzyme adenylyl cyclase that catalyzes the reaction in the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). These increased cAMP's lead to relaxation of bronchial smooth muscle. ⁸⁻¹⁰ Vilanterol demonstrated significant sub-nanomolar affinity for the β_2 -AR as good as salmeterol and superior to indacaterol, formoterol and olodaterol. ¹¹ Further, it shows higher intrinsic efficacy over salmeterol. Moreover, Vilanterol human recombinant $\beta_{1/2/3}$ -AR cAMP assays revealed that it has significantly greater β_2 -AR selectivity than formoterol, indacaterol and salbutamol. ¹² Vilanterol is an inhaled drug approved by FDA and used in combination with other drugs for the treatment of asthma & COPD patients. ¹³


More than one synthetic approach of Vilanterol was reported in the literature mainly in the public patents. However, the synthetic approach by Dammalapati et al is the most broadly used. ¹⁴ There is still considerable need of research on novel drugs and also their synthetic approaches for the development of long acting β_2 -AR bronchodilators as there are challenges for better activity and higher selectivity. ¹⁵ So we have been interested in synthesis of vilanterol because of its significance and high β_2 -AR potency and selectivity. Hence we attempted total synthesis of vilanterol in a novel and convenient way.



Scheme 1. Asthma and COPD potent drugs.

Results and Discussion


Scheme 2 shows the retrosynthesis of vilanterol (**1**). Its structure has one chiral centre, a secondary amine linkage, two ether linkages, aromatic phenol, and aromatic dichloro moieties. Vilanterol (**1**) can be broken down into two parts: oxazolidinone **10** and alkyl bromide **11**. The amino alcohol might be used to make chiral oxazolidinone **10** easily. The CBS reduction of **6**, afterwards hydrogenation of the azide and subsequent protection of both the -NH₂ and -OH groups, can yield the chiral center of the crucial intermediate **10**. Compound **6** was easily made from commercially available salicylaldehyde (**2**) by Friedel–Crafts acylation, then reduction and 2,2-DMP protection of both -OH groups.



Scheme 2. Retrosynthesis of Vilanterol.


We chose to manufacture the vilanterol (**1**) molecule because of its biological potential. We synthesized it in a non-infringing manner using commercially accessible and inexpensive salicylaldehyde (**2**) as a starting material and adopted this in order to effectively overcome disadvantages of harsh reaction conditions and expensive reagents. We were able to synthesize alpha-azidomethyl ketone **6** from salicylaldehyde in a simple and convenient way and then performed reduction on that azide compound which different from previously reported methods. Friedel–Crafts acylation of salicylaldehyde (**2**) in the presence of AlCl₃ and chloroacetyl chloride in dichloromethane (DCM) solvent led to the acylated product **3** in 75% yield. Chemoselective reduction of the aldehyde group in **3** with NaBH₄ and acetic acid at 5 °C to room temperature gave **4** in 85% yield. Now to protect both the phenolic -OH group and the primary alcoholic -OH group with single protection group, treatment of **4** with 2,2-DMP in the presence of a catalytic amount of PTSA in dichloromethane furnished the acetonide protected compound **5** in 90% yield. Conversion of chlorido to azide by using sodium azide in DMF at RT gave **6** in 95% yield. Conversion of the keto group into a chiral alcohol succeeded by using chiral CBS-oxazaborolidine. Reduction of keto compound **6** with (*R*)-CBS and BH₃.DMS in tetrahydrofuran (THF) solvent at 0 °C to RT delivered chiral compound **7** in 68% yield and >98% enantiomeric excess^[7].

Reduction of azide **7** by using 10% Pd/C in methanol solvent at RT gave amino alcohol **8** in 80% yield. Protection of the amino group in compound **8** with (BOC)₂O by using the base DIPEA in DMF solvent yielded compound **9**. Subsequent treatment with potassium *tert*-butoxide (KO^tBu) in dimethylformamide gave the oxazolidinone **10** in 70% yield. This intermediate proved extremely useful as it was a stable crystalline solid which could be alkylated very cleanly under mild conditions with a variety of electrophiles.



Scheme 3. Synthesis of oxazolidinone compound (**10**).

Thus, alkylation of **10** with bromide **11** in presence of KO^tBu and DMF at 0 °C to room temperature gave the coupled product **12** in 90% yield. Now the deprotection of the oxazolidine group was performed by using potassium trimethylsilanolate (KOSiMe₃). Treatment of **12** with two equivalents of potassium trimethylsilanolate in THF solvent under reflux conditions furnished the amino alcohol **13** in 95% yield. Finally, deprotection the acetonide under mild acidic conditions succeeded by treatment of **13** with 1N HCl solution at 0°C to RT to give (*R*)-vilanterol **1** in 70% yield. Analytical data of the final compound vilanterol (**1**) matched the previously reported data and overall yield from **2** is 11.9%



Scheme 4. Synthesis of vilanterol (1).

Conclusion

We report our efforts to develop a convenient and effective total synthesis of the β_2 -adrenoceptor agonist drug (R)-vilanterol, which has a longer action and is a more potent drug for COPD & asthma. Our synthetic route has advantages like commercially accessible inexpensive starting materials and reagents, standard reaction conditions, simple and broadly used reactions and satisfactory yields. The total synthesis of vilanterol was achieved in 11 steps.

Experimental Section

General. All reagents and solvents were obtained from commercial suppliers and were used without further purification. Analytical thin-layer chromatography (TLC) was performed on MERCK precoated silica gel 60-F254 (0.5 mm) aluminium plates. Visualization of the spots on TLC plates was achieved by UV light. ^1H and ^{13}C NMR spectra were recorded on Bruker 500 and 125 MHz instruments, respectively by making a solution of samples in DMSO using tetramethylsilane (TMS) as the internal standard. Chemical shifts for ^1H and ^{13}C are reported in parts per million (ppm) downfield from tetramethylsilane. Spin multiplicities are described as s (singlet), brs (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Coupling constant (J) values are reported

in Hertz (Hz). HRMS were determined with Agilent QTOF mass spectrometer 6540 series instrument. Wherever required, column chromatography was performed using silica gel (60-120). The reactions wherever anhydrous conditions were required were carried out under nitrogen positive pressure using freshly distilled solvents. All evaporation of solvents was carried out under reduced pressure using a rotary evaporator below 45 °C. Melting points were determined with an electrothermal digital melting point apparatus IA9100 and are uncorrected. The names of all the compounds given in the experimental section were taken from Chem Bio Draw Ultra, Version 12.0.

5-(2-Chloroacetyl)-2-hydroxybenzaldehyde (3). Chloroacetyl chloride (55.5 g) was added to a solution of AlCl₃ (133 g, 1 mol) in dry DCM (200 ml) over 30 min. Salicylaldehyde (**2**) (12.2 g, 0.1 mol) in dry DCM was added to the above mixture which was stirred at reflux temperature. After completion of reaction, it was poured onto crushed ice and extracted with ethyl acetate and then washed with brine. Concentration of the organic layer and recrystallization (hexane - ethyl acetate mixture) gave the pure compound **3** in 75% yield. ¹H NMR (CDCl₃, 300 MHz): δ 2.78 (s, 3H), 5.50 (s, 1H), 6.40-6.53 (m, 3H), 6.86-7.01 (m, 3H), 7.03-7.35 (m, 8H), 7.44 (t, 2H, *J* 7.5 Hz), 7.69 (s, 1H) ppm; ¹³C NMR (75 MHz, CDCl₃): δ 192.1, 165.8, 139.2, 131.7, 129.3, 128.8, 117.6, 45.3 ppm; IR (KBr): ν_{\max} 3414, 3055, 2925, 1611, 1454, 1217, 746, 705 cm⁻¹; ESI-MS: *m/z* 199[M+H]⁺.

2-Chloro-1-(4-hydroxy-3-(hydroxymethyl)phenyl)ethan-1-one (4). Sodium borohydride (294 mg, 7.8 mmol) was added portionwise to a solution of 5-(chloroacetyl)-2-hydroxybenzaldehyde **3** (1.50 g, 7.5 mmol) in acetic acid (38 mL) stirred at 5 °C (ice/water bath) under nitrogen. The mixture was stirred at rt. After completion of the reaction, water (40 mL) was added and the mixture was neutralized with saturated Na₂CO₃ solution. The mixture was extracted with ethyl acetate (4 × 50 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated to give a light red oil that turned solid upon standing. The crude residue was purified by column chromatography (silica gel, pentane–ethyl acetate, gradient from 9:1 to 2:8) and afforded a light pink solid product **4** (1.33 g, 6.6 mmol, 85% yield). ¹H NMR (DMSO-*d*₆, 400 MHz): δ 10.53 (s, 1H (OH)); 7.97 (d, 1H, *J* 2.0); 7.76 (dd, 1H, *J* 8.4, 2.4); 6.87 (d, 1H, *J* 8.4); 5.15 (br s, 1H (OH)); 5.04 (s, 2H (CH₂OH)); 4.50 (s, 2H (CH₂Cl)) ppm; ¹³C NMR (125 MHz, DMSO-*d*₆): δ 190.3, 159.9, 129.7, 129.6, 128.5, 126.0, 114.8, 58.2, 47.5 ppm; IR (KBr): ν_{\max} 3414, 3055, 2925, 1611, 1454, 1217, 746, 705 cm⁻¹; ESI-MS: *m/z* 201[M+H]⁺.

2-Chloro-1-(2,2-dimethyl-4H-benzo[*d*][1,3]dioxin-6-yl)ethan-1-one (5). To a suspension of 2-chloro-1-(4-hydroxy-3-(hydroxymethyl)phenyl)ethanone (**4**) (1.33 g, 6.6 mmol) and *p*-toluenesulfonic acid (0.0061 g, 0.035 mmol) in 33 mL of dichloromethane was added dropwise 2,2-dimethoxypropane (0.763 g, 7.3 mmol) in dichloromethane (17 mL). The suspension was stirred vigorously until it became homogeneous (light yellow). The reaction mixture was washed with saturated NaHCO₃ solution. The organic phase was separated and dried over MgSO₄. The solvent was evaporated under reduced pressure to give **5** as a solid (1.35 g, 5.6 mmol, 90% yield). ¹H NMR (CDCl₃, 300 MHz): δ 7.79 (dd, 1H, *J* 8.6, 2.2); 7.68 (d, 1H, *J* 2.0); 6.88 (d, 1H, *J* 8.8); 4.89 (s, 2H (CH₂O)); 4.63 (s, 2H (CH₂Cl)); 1.57 (s, 6H (C(CH₃)₂)) ppm; ¹³C NMR (75 MHz, CDCl₃): δ 189.7, 156.4, 129.2, 126.7, 126.2, 119.6, 117.4, 100.8, 60.6, 45.5, 24.8 ppm; IR (KBr): ν_{\max} 3414, 3055, 2925, 1611, 1454, 1217, 746, 705 cm⁻¹; ESI-MS: *m/z* 263[M+Na]⁺; HRMS: calcd for C₁₂H₁₃ClO₃Na, 263.0445, found: 263.0445.

2-Azido-1-(2,2-dimethyl-4H-benzo[*d*][1,3]dioxin-6-yl)ethan-1-one (6). A suspension of chloro ketone **5** (52 g, 181 mmol) in DMF (300 mL) was treated with sodium azide (12.24 g, 188 mmol) and the mixture was stirred at 20 °C for 2 h, by which time the mixture became homogeneous and red coloured. To the reaction mixture was added water, and a solid was formed. Filtrate the solid compound and washing with water gave the required azide **6** as a pale yellow solid (41.0 g, 95%). ¹H NMR (500 MHz, CDCl₃) δ 7.68 – 7.60 (m, 1H), 7.59 – 7.49 (m, 1H), 6.80 (t, *J* 8.8 Hz, 1H), 4.81 (s, 2H), 2.12 (s, 2H), 1.49 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 191.69, 156.52,

128.55, 126.89, 125.59, 119.71, 117.53, 100.86, 60.64, 54.45, 24.81. IR (KBr): ν_{\max} 3414, 3055, 2925, 1611, 1454, 1217, 746, 705 cm^{-1} ; ESI-MS: m/z 248[M+H]⁺.

(R)-2-Azido-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-ol (7). (*R*)-Tetrahydro-1-methyl-3,3-diphenyl-1*H*,3*H*-pyrrolo[1,2-*c*][1,3,2]oxazaborolidine in toluene (1 M, 7.5 mL) was added to THF (75 mL) and the solution was cooled to 0 °C. BH₃.DMS complex (1M solution in DMS, 125 mL) was added and the mixture was stirred under nitrogen for 15 min. A solution of **6** (24.7 g, 0.1 mol) in THF (250 mL) was added dropwise over 1.5 h at 5 °C. The mixture was stirred for a further 1h and then cautiously treated with 2 M HCl (100 mL). The reaction mixture was extracted with ether and the organic layer was washed with 2M HCl, saturated NaHCO₃, brine and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was chromatographed on silica gel column eluting with EtOAc–petroleum ether (10:90) to give **7** (16.99 g, 68%) as a white solid: ¹H NMR (500 MHz, DMSO) δ 7.14 (dd, *J* 8.4, 1.9 Hz, 1H), 7.06 (d, *J* 1.5 Hz, 1H), 6.78 (d, *J* 8.4 Hz, 1H), 4.85 (s, 2H), 4.40 (dt, *J* 23.0, 11.5 Hz, 1H), 2.65 (ddd, *J* 20.6, 12.8, 6.0 Hz, 2H), 1.50 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 150.67, 134.39, 125.80, 122.21, 119.34, 117.01, 99.58, 74.02, 60.98, 49.24, 24.86, 24.67.; ESI-MS: m/z 250[M+H]⁺.

(R)-2-Amino-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-ol (8). A solution of **7** (16.80 g, 68.10 mmol) in methanol (250 mL) was hydrogenated using 10% Pd/C (1.0 g). After completion of the reaction (indicated by TLC), the catalyst was collected by filtration, and washed with methanol. Distillation of the filtrate under reduced pressure gave **8** (5.86 g, 80%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J* 8.4 Hz, 1H), 6.99 (s, 1H), 6.79 (d, *J* 8.4 Hz, 1H), 4.84 (s, 2H), 4.53 (dd, *J* 7.7, 3.8 Hz, 1H), 2.97 (dd, *J* 12.6, 3.6 Hz, 1H), 2.77 (dd, *J* 12.7, 7.9 Hz, 1H), 1.53 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 150.65, 134.47, 125.80, 122.22, 119.33, 116.99, 99.58, 73.97, 60.97, 49.23, 24.76. IR (KBr): ν_{\max} 3359.45, 3299.56, 2992.47, 2822.59, 2608.22, 2515.07, 1886.40, 1596.08, 1434.27, 1324.59 cm^{-1} ; ESI-MS: m/z 224[M+H]⁺.

tert-Butyl (R)-(2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-hydroxyethyl)carbamate (9). To a stirred solution of **8** (12.40 g, 55.61 mmol) in dimethylformamide (150 ml) was added *N,N*-diisopropylethylamine (11.8 ml, 66.73 mmol) at 5 °C under nitrogen atmosphere and followed by (BOC)₂O (12.12 g, 55.61 mmol). The mixture was stirred at 20 °C for 3 h. The mixture was re-cooled to 0°C and quenched by the addition of 2M hydrochloric acid. The mixture was partitioned between ethyl acetate (1 L) and water (1 L) and the organic layer washed with brine and dried. The solvent was removed by distillation to give compound **9** (15.1 g, 96%) as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 7.11 (d, *J* 8.3 Hz, 1H), 6.98 (s, 1H), 6.78 (d, *J* 8.4 Hz, 1H), 5.02 (s, 1H), 4.81 (s, 2H), 4.74 – 4.65 (m, 1H), 3.41 – 3.16 (m, 2H), 1.53 (s, 6H), 1.44 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 156.95, 150.83, 133.81, 125.76, 122.25, 119.37, 117.08, 99.62, 79.85, 73.54, 60.94, 48.41, 28.40, 24.65. IR(KBr): ν_{\max} 3359.50, 3299.65, 3021.79, 2991.47, 2942.80, 2822.59, 2608.22, 2515.07, 1886.40, 1596.08, 1434.27, 1379.78, 746, 705 cm^{-1} ; ESI-MS: m/z 324[M+H]⁺.

(R)-5-(2,2-Dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one (10). Potassium *tert*-butoxide (KO^tBu) (2.65 g, 66.2 mmol) was added to a stirred solution of **9** (16.40 g, 50.71 mmol) in dimethylformamide (150 mL) at 5 °C under nitrogen atmosphere. The mixture was stirred at 20 °C for 3 h. The mixture was cooled to 0 °C and quenched by the addition of 2M hydrochloric acid. The mixture was partitioned between ethyl acetate (1000 mL) and water (1000 mL). The organic phase was washed with brine (250mL), dried and evaporated. The solid was triturated with diethyl ether to give **10** (8.84 g, 70%) as a white crystalline solid: $[\alpha]^{20}_D$ (c 1.379 in CHCl₃); Chiral HPLC on a Whelk-O 1 column (25 cm × 0.46 cm) eluting with ethanol–heptane (35 : 65) at a flow rate of 1 mL min⁻¹ and detecting at 215 nm: *t*_R 8.11 min, 0.9%; *t*_R 10.38 min, 99.1% (racemate: *t*_R 7.99 min and 10.50 min). ¹H NMR (400 MHz, CDCl₃) δ 7.18 – 7.12 (m, 1H), 7.05 – 7.00 (m, 1H), 6.88 – 6.79 (m, 1H), 5.54 (q, *J* 8.1 Hz, 1H), 5.40 (s, 1H), 4.89 – 4.79 (s, 2H), 3.96 – 3.87 (m, 1H), 3.57 – 3.46 (m, 1H), 1.55 – 1.53 (s, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 162.67, 159.96, 151.85, 130.13, 125.98, 122.59, 119.87, 117.57, 99.89, 77.91, 60.80, 48.31,

24.74.; IR (KBr): ν_{\max} .3274.64, 2994.28, 2849.32, 1719.62, 1502.09, 1438.54, 1267.33, 1130.90, 1077.58, 868.59, 821.14, 694.24 cm^{-1} ; ESI-MS: m/z 250[M+H]⁺. HRMS: calcd for C₁₃H₁₆NO₄, 250.10854, found: 250.10738.

(R)-3-(6-(2-((2,6-Dichlorobenzyl)oxy)ethoxy)hexyl)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one (12). Potassium *tert*-butoxide (KO^tBu) (4.72g, 4.216 mmol) was added to the solution of oxazolidine compound **10** (10 g, 4.016 mmol) in DMF at room temperature. The mixture was stirred for 1 h at room temperature. Bromide **11** (16.8 g, 4.417 mmol) in DMF was added and stirring was continued at RT. After completion of the reaction, cold water was added and the mixture was extracted with ethyl acetate. The separated organic layer was washed with brine and dried on Na₂SO₄. Removal of the organic layer afforded the title compound **12** as a pale-yellow oil in 90% Yield. ¹H NMR (400 MHz, CDCl₃) δ 7.22 (t, J 7.7 Hz, 2H), 7.12 – 7.00 (m, 2H), 6.93 (dd, J 10.6, 1.8 Hz, 1H), 6.77 (dd, J 12.5, 8.4 Hz, 1H), 5.30 (dt, J 12.0, 8.2 Hz, 1H), 4.74 (t, J 9.6 Hz, 4H), 3.76 (dt, J 11.3, 8.7 Hz, 1H), 3.65 – 3.61 (m, 2H), 3.53 (dd, J 7.4, 2.6 Hz, 2H), 3.39 – 3.15 (m, 5H), 2.10 (s, 3H), 1.53 – 1.43 (m, 7H), 1.27 (m, 4H).

¹³C NMR (101 MHz, CDCl₃) δ 157.88, 151.73, 136.96, 133.43, 130.56, 129.98, 128.42, 125.70, 122.32, 119.86, 117.58, 99.87, 74.26, 71.20, 70.00, 67.56, 60.82, 52.19, 44.20, 29.60, 28.03, 27.36, 26.52, 25.81, 24.81, 24.70.

IR (KBr): ν_{\max} .3446.58, 3349.63, 2996.59, 2944.82, 2878.42, 2215.32, 2101.99, 1681.71, 1609.77, 1583.91, 1497.28, 1317.47, 1118.78, 1059.37 cm^{-1} ; ESI-MS: m/z 552[M+H]⁺; HRMS: calcd for C₂₈H₃₆Cl₂NO₆, 552.19197, found: 552.1918.

(R)-2-((6-(2-((2,6-Dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-ol (13). Potassium trimethylsilanolate (KOSiMe₃) was added to the compound **12** in THF at room temperature. Then the mixture was stirred at reflux temperature until completion of reaction. The mixture was cooled the RM to 0°C to 5°C and the pH was adjusted 6 – 7 with sodium phosphate solution before work up with ethyl acetate. Then separated organic layer was washed with brine and then dried on Na₂SO₄. Removal of the solvent to afforded the title compound **13** as a pale-yellow oil in 95% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.28 (m, 2H), 7.20 – 7.11 (m, 2H), 7.01 (s, 1H), 6.78 (dd, J 8.3, 2.9 Hz, 1H), 4.85 – 4.81 (m, 4H), 4.68 (d, J 6.3 Hz, 1H), 3.76 (s, 1H), 3.73 – 3.68 (m, 2H), 3.61 (dt, J 6.5, 4.4 Hz, 2H), 3.49 – 3.43 (m, 2H), 2.88 (dd, J 12.2, 3.4 Hz, 1H), 2.74 – 2.61 (m, 3H), 1.60 – 1.51 (m, 10H), 1.37 – 1.29 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 150.96, 136.97, 133.81, 133.14, 130.29, 128.40, 125.57, 121.71, 119.21, 117.65, 99.56, 71.31, 70.84, 70.07, 70.01, 67.57, 61.12, 56.76, 49.21, 29.73, 27.09, 25.98, 24.89, 24.65. IR (KBr): ν_{\max} .3457.53, 3380.39, 2981.77, 2856.91, 1698.01, 1604.50, 1510.80, 1378.49, 1255.48, 1148.13, 1051.10, 954.96, 842.2, 751.81, 575.01 cm^{-1} ; ESI-MS: m/z 526[M+H]⁺; HRMS: calcd for C₂₇H₃₈Cl₂NO₅, 526.2127, found: 526.21165.

(R)-4-(2-((6-(2-((2,6-Dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol (1). Acetonide compound **13** dissolved in acetone and cooled to 0 °C to 5 °C. Then slowly 1N HCl solution was added and the mixture was stir for 1h at the same temperature. After completion of reaction dichloromethane and water were added. Then separated red organic layer was washed with NaHCO₃ solution and brine solution and then dried on Na₂SO₄. Removal of the organic layer and purification by column chromatography afforded the title compound as a pale-yellow oil in 70% yield.

¹H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 8.71 (s, 1H), 7.51 – 7.47 (m, 2H), 7.42 – 7.36 (m, 1H), 7.32 (d, J 2.0 Hz, 1H), 7.05 (dd, J 8.2, 2.2 Hz, 1H), 6.78 (d, J 8.2 Hz, 1H), 5.94 (s, 1H), 5.03 (t, J 5.1 Hz, 1H), 4.84 (d, J 8.1 Hz, 1H), 4.69 (s, 2H), 4.48 (d, J 4.3 Hz, 1H), 3.64 – 3.58 (m, 2H), 3.51 (dd, J 5.8, 3.7 Hz, 2H), 3.37 (dd, J 11.7, 5.2 Hz, 3H), 3.03 – 2.85 (m, 4H), 1.63 (d, J 5.9 Hz, 2H), 1.52 – 1.44 (m, 2H), 1.34 – 1.25 (m, 4H).

¹³C NMR (126 MHz, CDCl₃) δ 154.44, 135.88, 132.25, 130.10, 128.96, 127.38, 125.99, 125.65, 114.88, 70.11, 68.93, 67.74, 66.47, 53.27, 46.95, 28.41, 25.53, 25.22, 24.64, 22.79. IR (KBr) ν_{\max} .3444.16, 2936.99, 2876.71,

1629.86, 1563.78, 1423.34, 1262.54, 1110.22, 769.78, 608.50 cm⁻¹; ESI-MS: *m/z* 486.17[M+H]⁺; HRMS: calcd. for C₂₄H₃₄Cl₂NO₅, 486.1814, found: 486.18137.

Acknowledgements

The authors are thankful to the Department of Chemistry, Telangana University and Osmania University, Telangana, India.

Supplementary Material

Supplementary data associated with this article is available in the Supplementary Material.

References

1. Yi, C. ; Xing, G. ; Wang, S. ; Li, X. ; Liu, Y. ; Li, J. ; Lin, B. ; Yiu-Ho Woo, A. ; Zhang, Y. ; Pan, L. ; Cheng, M. *Bioorg. Med. Chem.* **2020**, *28*, 115178.
<https://doi.org/10.1016/j.bmc.2019.115178>
2. Barnes, P. J. *Nat. Rev. Immunol.* **2008**, *8*, 183-192.
<https://doi.org/10.1038/nri2254>
3. Brown, A. D. ; Bunnage, M.E.; Glossop, P. A.; James, K.; Jones, R.; Lane, C. A. L. ; Lewthwaite, R. A. ; Mantell, S. ; Perros-Huguet, C.; Price, D. A. ; Trevethick, M.; Webster, R. *Bioorg. Med. Chem.Lett.* **2007**, *17*, 4012-4015.
<https://doi.org/10.1016/j.bmcl.2007.04.081>
4. Fusco, L. ; Mores, S. ; Valente, M. ; Malerba, ; Montuschi, P. *Curr. Med. Chem.*, **2013**, *20*, 1477-1495.
<https://doi.org/10.2174/0929867311320120003>
5. Procopiou, P. A. ; Barrett, V. J. ; Bevan, N.J. ; Biggadike, K. ; Box, P.C. ; Butchers, P.R. ; Coe, D.M. ; Conroy, R. ; Emmons, A. ; Ford, A.J. ; Holmes, D.S. ; Horsley, H. ; Kerr, F. ; Cheung, A.M.L.K. ; Looker, B.E. ; Mann, I.S. ; McLay, I.M. ; Morrison, V.S. ; Mutch, P.J. ; Smith, C.E. ; Tomlin, P. *J. Med. Chem.* **2010**, *53*, 4522–4530.
<https://doi.org/10.1021/jm100326d>
6. Xing, G.; Yiu-Ho Woo, A. ; Pan, L. ; Lin, B. ; Cheng, M.-S. *J. Med. Chem.* **2020**, *63*, 24, 15218.
<https://doi.org/10.1021/acs.jmedchem.0c01195>
7. "FDA approves BreoEllipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.
<https://wayback.archive-it.org/7993/20170112023857/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm>
8. Ejiogor, S.; Turner, A. M. *Clin. Med. Circ. Respir. Pulm. Med.* **2013**, *7*, 17–34.
<https://doi.org/10.4137/CCRPM.S7211>
9. Billington, C. K.; Penn, R. B.; Hall, I. P. *Handb. Exp. Pharmacol.* **2017**, *237*, 23–40.
https://link.springer.com/chapter/10.1007/164_2016_64
10. Burkes, R.M. ; Panos, R. J. *J. Exp. Pharmacol.* **2020**, *12*, 589-602.

<https://doi.org/10.2147/JEP.S259328>

11. Slack, R. J.; Barrett, V. J.; Morrison, V. S.; Sturton, R. G.; Emmons, A. J.; Ford, A. J.; Knowles, R. G. *J. Pharmacol. Exp. Ther.* **2013**, *344*, 218–230.
<https://doi.org/10.1124/jpet.112.198481>
12. Cazzola, M.; Calzetta, L.; Matera, M. G. *Am. J. Respir. Crit. Care Med.*, **2010**, *181*, A4451.
<https://doi.org/10.1111/j.1476-5381.2011.01216.x>
13. <https://www.drugbank.ca/drugs/DB09082>
14. Ayazoddin, A. K. ; Subba Reddy, B. V. ; Ravithey, S. L. *Bioorg. Med. Chem.* **2021**, *41*, 116-212.
<https://doi.org/10.1016/j.bmc.2021.116212>
15. Xing, G.; Yi, C.; Dou, P.; Zhi, Z.; Lin, B.; Cheng, M. *Expert Opin. Ther. Pat.* **2021**, *31*, 239-246
<https://doi.org/10.1080/13543776.2021.Xing, 1865312>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)